Rifampicin was tried in the treatment of scarlet fever and effects to the eradication of pharyngeal streptococcus haemolyticus and fever were observed, giving the dose of 20 mg/Kg Rifampicin in 57 and 30 mg/Kg in 10 child patients for 7 days.
The results were evaluated as follows:
In the group given 20 mg/Kg Rifampicin, the effects were classified as: 27 excellent, 9 good, 16 fair, and 5 ineffective.
In the group given 30 mg/Kg Rifampicin, 5 excellent, 2 good, and 3 fair.
From above results, Rifampicin can be registered as first choice drug for scarlet fever as effective as erythromycin.
Besides, it should be a great advantage in the use that it needs only once a day dose.
Two cases of exanthema and transient hematuria, respectively, were encountered as side effects.

View full abstract

Cefazolin (CEZ) is a new cephalosporin antibiotic. According to earlier studies, it's antibacterial activity, absorption, urinary excretion and organ concentrations are similiar to those of cephaloridine (CER). In this clinical study, it's therapeutic effect was compared with that of CER in bacterial pneumonia.
This was made on double blind method. Both antibiotics were given to 43 patients (CEZ: 22cases, CER: 21 cases) in a dosage of 1 g (500 mg×2) daily intramuscularly.
Body temperature, cough, sputum and dyspnea were checked, white blood cell counts, CRP and roentgenogram of the chest were taken on the 7th and 14th day from the beginning of their administration.
Improvements of the chest roentgenogram findings were noted in 72.7% of CEZ administered group and 71.5% of CER administered group on the 14th day of treatment. There was no statistically significant differences in clinical effectiveness between CEZ and CER on other clinical signs and symptoms.
The data indicated that CEZ is an antibiotic as effective as CER.
No side effects were seen in all patients.

View full abstract

[in Japanese]

View full abstract